Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks 
OpenAI Hires OpenClaw Creator Peter Steinberger to Advance Next-Generation AI Agents 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
WALTHAM, Mass., April 27, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:
- Deutsche Bank Annual Health Care Conference
Tuesday, May 8, 2018 at 8:40 a.m. ET
Location: Boston, MA - Bank of America Merrill Lynch Health Care Conference
Tuesday, May 15, 2018 at 4:20 p.m. PT (7:20 p.m. ET)
Location: Las Vegas, NV
To access the live webcasts, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of each event will be archived on the site for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638
